Life Molecular Imaging (LMI) and SOFIE Biosciences have announced an expansion of their partnership and licensing agreement to provide and distribute Neuraceq® from SOFIE's radiopharmaceutical manufacturing site in Cleveland, Ohio. The availability of Neuraceq® began on April 4, 2024.

Neuraceq® is an FDA-approved imaging agent used to detect beta-amyloid plaques in the brains of adult patients with cognitive impairment undergoing evaluation for Alzheimer's disease and other cognitive decline causes. It serves as a vital imaging biomarker for characterizing subjects assessed for treatment eligibility with newly approved anti-amyloid drugs or for enrollment in clinical trials supporting drug development in neurodegenerative diseases.

Ludger Dinkelborg, Ph.D., Managing Director at LMI, expressed excitement about the expanded distribution network, stating, "By adding Cleveland to our distribution network, Life Molecular Imaging is thrilled to provide additional availability of Neuraceq®, an important imaging tool for the detection of beta-amyloid plaques in the brain." He emphasized the benefits for physicians, patients, and pharmaceutical partners in routine clinical and research use.

Brian Schumer, PharmD, SOFIE COO, echoed this sentiment, emphasizing SOFIE's commitment to expanding Neuraceq® availability. "We are excited to bring Neuraceq® availability to another SOFIE network site. The continued growth and advancement in Alzheimer's disease diagnosis and treatment is very promising for patients and their families," he stated.